Chapters Transcript Video Immunotherapy in Lung Cancer Treatment Thoracic surgeon Stephen Broderick provides updates on the use of immunotherapy in lung cancer treatment. Share Fast Facts How effective is immunotherapy when treating lung cancer? Learn more. Click to Tweet mm. Yeah. Mhm. Yeah. Checkpoint inhibitors are a new class, relatively new class of drugs in the sort of overall therapeutic class of immuno therapeutic agents which are being employed much more frequently now for advanced stage non small cell lung cancer patients. Where we've seen terrific uh and durable responses to therapy. We have now taken the next step in collaboration with certainly our medical oncologists here at Hopkins and another other number of other centres to employ those drugs in the neo adjuvant setting that is to deliver those drugs to patients before surgery. So in patients with earlier stage cancers who are going to proceed to surgery for their lung cancer. But we give them the neo adjuvant therapy or the before surgical therapy of these immunotherapy agents. And we've seen tremendous responses in our early stage Phase one trials which we uh perform that study in conjunction with Memorial Sloan Kettering and was published in the new England Journal, where we saw a 45% rate of major pathologic response in those tumors. So that when we Respect The lung cancer and the pathologists look at it under the microscope, over 90% of the tumor cells have been killed by the immunotherapy. And we think that that is going to be a marker for or is prognostic for good responses to therapy and hopefully improve survival. A number of our medical oncologists and I have been privileged to serve on the steering committee for the checkmate 816 trial, which is a prospective randomized trial comparing chemotherapy before surgery to chemotherapy with the addition of immunotherapy before surgery That trial is completed. Uh And the preliminary results are incredibly encouraging. We see a much higher rate of pathologic response in the patients who received immunotherapy compared to standard of care chemotherapy alone. Uh That data was recently presented at the A. C. R. Meeting. We have to wait longer for the primary endpoint of overall survival to mature. But we're very encouraged by those results. We also have a number of other trials regarding immunotherapy in the neo adjuvant setting that are still currently accruing at Hopkins And I think that's a tremendous opportunity for our group and the lung cancer community and certainly for lung cancer patients uh as a whole. So uh a number of our medical oncologists and I have been privileged to serve on the steering committee for the checkmate 816 trial. Which is a prospective randomized trial comparing chemotherapy before surgery to chemotherapy with the addition of immunotherapy before surgery that trial is completed. Uh And the preliminary results are incredibly encouraging. We see a much higher rate of pathologic response in the patients who received immunotherapy compared to standard of care chemotherapy alone. Uh That data was recently presented at the A. C. R. Meeting. We have to wait longer for the primary endpoint of overall survival to mature. But we're very encouraged by those results. We also have a number of other trials regarding immunotherapy in the neo adjuvant setting that are still currently accruing at Hopkins. And I think that's a tremendous opportunity for our group and the lung cancer community, and certainly for lung cancer patients, uh, as a whole. Oh, that's good, Good. Great Gwen, awesome. Thank. Created by Related Presenters Stephen Broderick, MD Assistant Professor of Surgery
Facebook
Twitter
YouTube
LinkedIn
Instagram
E-News
BROADCASTMED